MedTrace Logo

SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI®

NCT05546398 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2022-12-01

No results posted yet for this study

Summary

In this study, a survey of office-based cardiologists and lipid management specialists will be conducted on treatment decisions for NUSTENDI® (bempedoic acid 180 mg fixed dose combination \[FDC\] with ezetimibe 10 mg) followed by a retrospective chart review of patients at high and very-high cardiovascular risk with hypercholesterolemia or mixed dyslipidemia who were treated with FDC as add-on to treatment with maximally tolerated statin therapy in routine clinical practice.

Conditions

Interventions

DRUG

Bempedoic Acid 180Mg/Ezetimibe 10Mg Tab

No study drug was administered during this study.

OTHER

No study drug

No study drug was administered during this study.

Sponsors & Collaborators

  • Daiichi Sankyo Germany

    collaborator UNKNOWN

  • Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-22
Primary Completion
2022-11-17
Completion
2022-11-17

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05546398 on ClinicalTrials.gov